Physician Preferences and Clinical Experience with Rabeprazole–Domperidone in Acid-Related Disorders: Insights from the Power Physician Survey 3.0 in India
DOI:
https://doi.org/10.59793/xwjv5445Keywords:
Gastroesophageal reflux disease,, proton pump inhibitors,, real-world evidence,, physician perception,, domperidone- based combinationsAbstract
Gastroesophageal reflux disease (GERD) is a common and chronic acid-related disorder that significantly
affects quality of life. Proton pump inhibitors (PPIs) remain the cornerstone of therapy, often prescribed in combination with
prokinetics such as domperidone to enhance symptomatic relief. This survey aimed to assess physician perceptions, prescribing
patterns, and key factors determining the choice of PPI–domperidone combinations in India. Methods: A cross-sectional,
perception-based digital survey (Power Physician Survey 3.0) was conducted among 3,260 physicians across India. A structured
questionnaire captured information on patient load, preferred treatment strategies, time to symptom relief, recurrence rates,
and factors guiding the selection of specific PPI–domperidone combinations. Responses were analyzed using descriptive
statistics. Results: Over half of the respondents (51.6%) preferred prescribing a PPI–domperidone combination rather than PPI
monotherapy. The rabeprazole–domperidone (RD) combination emerged as the most preferred regimen (80.1%), primarily for
its rapid acid inhibition (46.6%), better tolerability (18.3%), and cost-effectiveness (13%). About half of the physicians observed
symptomatic relief within 2 to 3 days (50.6%), with 82.8% perceiving lower recurrence rates and 88.7% reporting improved
patient adherence. On preference ranking, RD was selected as the first choice by 80.1% of physicians, followed by pantoprazole–
domperidone (10.4%), omeprazole–domperidone (4.8%), and esomeprazole–domperidone (4.7%). The combination was also
rated most effective for night-time heartburn (90%) and preferred for patients with comorbidities (86.3%). Conclusion: The
findings highlight a strong real-world preference for the RD combination in GERD management, driven by its rapid action,
safety, and patient-centered benefits including improved adherence, symptom control, and reduced recurrence. These insights
emphasize the importance of balancing efficacy, tolerability, and affordability in clinical decision-making for acid-related
disorders in India.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Indian Journal Of Clinical Practice
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
How to Cite
